Affinity Clinical Research
Latest News and Information
Why it is Essential to have Patient Input into Clinical Trial Design
The Iqvia Institute released a report last month titled The Changing Landscape of Research and Development Innovation1. The report is a fascinating insight into the world of clinical research and provides evidence to support what many in the industry already know:...
read moreHereditary Haemochromatosis Trial meets Primary Endpoint
Last Thursday, La Jolla Pharmaceuticals issued a press release stating that the results of the Interim Analysis of the LJ401-HH01 (HERCULES) study confirmed the study had met its primary endpoint. The change in Transferrin Saturation (TSAT) from baseline to the end of...
read moreImmunotherapy – An overview
Immunotherapy is a growing therapeutic area for the treatment of cancer both in Australia and other countries and refers to any treatment that uses the patient’s natural defence system (immune system) to fight cancer2. Several Checkpoint Inhibitors have been approved for use in Australia in the last few years, including pembrolizumab, nivolumab and ipilimumab.
read moreFirst Patient Enrolled in HCC trial
Affinity Oncology reached another milestone today by enrolling its first Hepatocelluar Carcinoma (HCC) patient into a clinical trial. Liver cancer is the sixth most common cancer in the world, and hepatocellular carcinoma (HCC) is the most common type of liver...
read moreHow Affinity Works
Affinity is NOT a one-size-fits-all company. We tailor our services to the individual medical practitioner and to the research project. Research with Affinity does not look the same as the traditional research institution. One example of how Affinity works can be seen...
read moreInvestigator-Initiated Research – Common Mistakes
Investigator-Initiated research is exciting research. It is attempting to answer questions asked by those at the coal face. Who better than clinicians to know what problems face our patient day-to-day? I have been involved with Investigator-Initiated research for...
read moreStaffing Clinical Trials
The biggest expense of a research project is people. Hiring qualified, experienced staff is not cheap. It is, however, necessary. Without the right people, it is unlikely the research project will make it out of the starting gates, let alone to the...
read moreApproval of New Lung Cancer Trial on World Lung Cancer Day
It is very fitting that on World Lung Cancer Day we can announce the approval of the MERU study, a new trial for patients with extensive stage Small Cell Lung Cancer. The MERU study will evaluate the efficacy of rovalpituzumab tesirine (Rova-T) as maintenance therapy...
read moreHead and Neck study Now Open
We are excited to announce the Dynavax DV3-MEL-01 study for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) is now open to recruitment. Head and Neck cancer includes cancer of the tongue, gum, mouth, salivary glands, tonsils, pharynx, nasal...
read moreMelanoma study Now Open
We are excited to announce the Dynavax DV3-MEL-01 study for metastatic or advanced melanoma is now open to recruitment (and we have already recruited our first patient!). More information about the study can be found here. If you would to discuss this study, you can...
read more
Why it is Essential to have Patient Input into Clinical Trial Design
The Iqvia Institute released a report last month titled The Changing Landscape of Research and Development Innovation1. The report is a fascinating insight into the world of clinical research and provides evidence to support what many in the industry already know:...
read moreHereditary Haemochromatosis Trial meets Primary Endpoint
Last Thursday, La Jolla Pharmaceuticals issued a press release stating that the results of the Interim Analysis of the LJ401-HH01 (HERCULES) study confirmed the study had met its primary endpoint. The change in Transferrin Saturation (TSAT) from baseline to the end of...
read moreImmunotherapy – An overview
Immunotherapy is a growing therapeutic area for the treatment of cancer both in Australia and other countries and refers to any treatment that uses the patient’s natural defence system (immune system) to fight cancer2. Several Checkpoint Inhibitors have been approved for use in Australia in the last few years, including pembrolizumab, nivolumab and ipilimumab.
read moreFirst Patient Enrolled in HCC trial
Affinity Oncology reached another milestone today by enrolling its first Hepatocelluar Carcinoma (HCC) patient into a clinical trial. Liver cancer is the sixth most common cancer in the world, and hepatocellular carcinoma (HCC) is the most common type of liver...
read moreHow Affinity Works
Affinity is NOT a one-size-fits-all company. We tailor our services to the individual medical practitioner and to the research project. Research with Affinity does not look the same as the traditional research institution. One example of how Affinity works can be seen...
read moreInvestigator-Initiated Research – Common Mistakes
Investigator-Initiated research is exciting research. It is attempting to answer questions asked by those at the coal face. Who better than clinicians to know what problems face our patient day-to-day? I have been involved with Investigator-Initiated research for...
read moreStaffing Clinical Trials
The biggest expense of a research project is people. Hiring qualified, experienced staff is not cheap. It is, however, necessary. Without the right people, it is unlikely the research project will make it out of the starting gates, let alone to the...
read moreApproval of New Lung Cancer Trial on World Lung Cancer Day
It is very fitting that on World Lung Cancer Day we can announce the approval of the MERU study, a new trial for patients with extensive stage Small Cell Lung Cancer. The MERU study will evaluate the efficacy of rovalpituzumab tesirine (Rova-T) as maintenance therapy...
read moreHead and Neck study Now Open
We are excited to announce the Dynavax DV3-MEL-01 study for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) is now open to recruitment. Head and Neck cancer includes cancer of the tongue, gum, mouth, salivary glands, tonsils, pharynx, nasal...
read moreMelanoma study Now Open
We are excited to announce the Dynavax DV3-MEL-01 study for metastatic or advanced melanoma is now open to recruitment (and we have already recruited our first patient!). More information about the study can be found here. If you would to discuss this study, you can...
read more